Impact of TP53 mutations on the efficacy of CAR-T cell therapy in cancer
The efficacy of chimeric antigen receptor (CAR)-T therapy may not match initial expectations due to the influence of multiple circumstances, some of which cannot be predicted. CAR-T treatment groups include high-risk patients, particularly those with TP53 mutations. A significant body of research ha...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2024-12-01
|
| Series: | Exploration of Immunology |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/Journals/ei/Article/1003176 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846116348405481472 |
|---|---|
| author | Regina Mirgayazova Raniya Khadiullina Maria Filimonova Vitaly Chasov Emil Bulatov |
| author_facet | Regina Mirgayazova Raniya Khadiullina Maria Filimonova Vitaly Chasov Emil Bulatov |
| author_sort | Regina Mirgayazova |
| collection | DOAJ |
| description | The efficacy of chimeric antigen receptor (CAR)-T therapy may not match initial expectations due to the influence of multiple circumstances, some of which cannot be predicted. CAR-T treatment groups include high-risk patients, particularly those with TP53 mutations. A significant body of research has demonstrated that mutations in the TP53 gene play a pivotal role in cancer development and progression. Any aberration in the TP53 gene in cancer is invariably associated with complications and a poor prognosis. Moreover, mutations in the TP53 gene have been observed to correlate with resistance to conventional chemotherapy, prompting the use of alternative therapeutic approaches, including CAR-T therapy. However, there is a possibility that abnormalities in the TP53 gene may affect patients after CAR-T cell administration reducing the efficacy of therapy. This review examines the link between TP53 mutations in cancer and the efficacy of CAR-T therapy, as well as the potential implications of this aspect in therapeutic planning. |
| format | Article |
| id | doaj-art-c51c912c26154758bb0780bba9a72bb5 |
| institution | Kabale University |
| issn | 2768-6655 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Open Exploration Publishing Inc. |
| record_format | Article |
| series | Exploration of Immunology |
| spelling | doaj-art-c51c912c26154758bb0780bba9a72bb52024-12-19T05:13:06ZengOpen Exploration Publishing Inc.Exploration of Immunology2768-66552024-12-014683785210.37349/ei.2024.00176Impact of TP53 mutations on the efficacy of CAR-T cell therapy in cancerRegina Mirgayazova0https://orcid.org/0000-0001-6767-2571Raniya Khadiullina1https://orcid.org/0000-0003-3521-5995Maria Filimonova2https://orcid.org/0000-0001-8619-9687Vitaly Chasov3https://orcid.org/0000-0003-2679-231XEmil Bulatov4https://orcid.org/0000-0003-2961-0032Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia; Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), 119048 Moscow, RussiaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, RussiaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, RussiaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, RussiaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia; Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), 119048 Moscow, Russia; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, RussiaThe efficacy of chimeric antigen receptor (CAR)-T therapy may not match initial expectations due to the influence of multiple circumstances, some of which cannot be predicted. CAR-T treatment groups include high-risk patients, particularly those with TP53 mutations. A significant body of research has demonstrated that mutations in the TP53 gene play a pivotal role in cancer development and progression. Any aberration in the TP53 gene in cancer is invariably associated with complications and a poor prognosis. Moreover, mutations in the TP53 gene have been observed to correlate with resistance to conventional chemotherapy, prompting the use of alternative therapeutic approaches, including CAR-T therapy. However, there is a possibility that abnormalities in the TP53 gene may affect patients after CAR-T cell administration reducing the efficacy of therapy. This review examines the link between TP53 mutations in cancer and the efficacy of CAR-T therapy, as well as the potential implications of this aspect in therapeutic planning.https://www.explorationpub.com/Journals/ei/Article/1003176tp53mutationcar-timmunotherapycancer |
| spellingShingle | Regina Mirgayazova Raniya Khadiullina Maria Filimonova Vitaly Chasov Emil Bulatov Impact of TP53 mutations on the efficacy of CAR-T cell therapy in cancer Exploration of Immunology tp53 mutation car-t immunotherapy cancer |
| title | Impact of TP53 mutations on the efficacy of CAR-T cell therapy in cancer |
| title_full | Impact of TP53 mutations on the efficacy of CAR-T cell therapy in cancer |
| title_fullStr | Impact of TP53 mutations on the efficacy of CAR-T cell therapy in cancer |
| title_full_unstemmed | Impact of TP53 mutations on the efficacy of CAR-T cell therapy in cancer |
| title_short | Impact of TP53 mutations on the efficacy of CAR-T cell therapy in cancer |
| title_sort | impact of tp53 mutations on the efficacy of car t cell therapy in cancer |
| topic | tp53 mutation car-t immunotherapy cancer |
| url | https://www.explorationpub.com/Journals/ei/Article/1003176 |
| work_keys_str_mv | AT reginamirgayazova impactoftp53mutationsontheefficacyofcartcelltherapyincancer AT raniyakhadiullina impactoftp53mutationsontheefficacyofcartcelltherapyincancer AT mariafilimonova impactoftp53mutationsontheefficacyofcartcelltherapyincancer AT vitalychasov impactoftp53mutationsontheefficacyofcartcelltherapyincancer AT emilbulatov impactoftp53mutationsontheefficacyofcartcelltherapyincancer |